The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).
 
In Hae Park
Research Funding - Roche
 
Gun Min Kim
No Relationships to Disclose
 
Jee Hyun Kim
Research Funding - Ono Pharmaceutical
 
Hanjo Kim
No Relationships to Disclose
 
Kyong Hwa Park
No Relationships to Disclose
 
Yeon Hee Park
Honoraria - Merck; Novartis; Pfizer
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca; Eisai; Pfizer
Travel, Accommodations, Expenses - Merck; Novartis
 
Sun Kyung Baek
No Relationships to Disclose
 
Sung Hoon Sim
No Relationships to Disclose
 
Hee Kyung Ahn
No Relationships to Disclose
 
Gyeong-Won Lee
No Relationships to Disclose
 
Kyoung Eun Lee
No Relationships to Disclose
 
Ji Eun Lee
No Relationships to Disclose
 
Seungtaek Lim
No Relationships to Disclose
 
Kyung Hae Jung
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Roche; Takeda
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Hanmi; Lilly; medpacto; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Novartis; Roche/Genentech
Other Relationship - Roche